Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
WISeKey to ConnectWISeRobot.CH to the WISeSat.Space Constellation protected by SEALSQ Post-Quantum Cryptography; The Robot PoC will be showcased at WISeKEY’s CEO Carlos Moreira’s next public...
-
SIKA BAUT GLOBALES FERTIGUNGSNETZWERK IN WACHSTUMSMÄRKTEN MIT FÜNF NEUEN WERKEN AUS Sika hat ihr globales Fertigungsnetzwerk mit der Eröffnung fünf neuer Standorte in den USA, Argentinien, Kolumbien,...
-
SIKA EXPANDS ITS GLOBAL MANUFACTURING FOOTPRINT ACROSS GROWTH MARKETS WITH FIVE NEW PLANTS Sika has expanded its global manufacturing network with the opening of five new sites located in the United...
-
Data published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...
-
WISeSat and SEALCOIN Formalize Strategic Collaboration to Enable Satellite-Based Machine Transactions Geneva, Switzerland — February 2, 2026 - WISeKey International Holding Ltd (“WISeKey”) (SIX:...
-
2 February 2026, London: 21shares, a leading global provider of crypto ETPs, is pleased to announce the appointment of Stephen Coltman as Head of Macro, effective at the beginning of February. This...
-
Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancersDosimetry data highlight Radio-DARPins as vector for...
-
WISeSat.Space Brought Together Global Thought-Leaders to Davos to Address Quantum Security in Space Watch the entire roundtable discussion here: https://youtu.be/YDKj1nxbPdo Davos, Switzerland –...
-
30 January 2026, 08:30 CET The Government of the Republic of Liberia and ArcelorMittal (“the Company”) have signed an amendment to the existing Mineral Development Agreement (MDA), which was...
-
Data from up to 42 months of treatment reinforce lucerastat’s potential as a first-in-class oral substrate reduction therapy addressing key unmet needs across the Fabry populationThe company is...